Qubit Pharmaceuticals, a deeptech company focused on discovering drug candidates through accelerated molecular simulation powered by high-performance computing and quantum computing, announces the appointment of Romain Delassus as Chief Product and Engineering Officer (Director of Products and Information Systems).
A 37-year-old, Romain Delassus joins the company after more than a decade of public-sector experience, where he led large-scale digital projects. An alumnus of the École Polytechnique and an engineer from the Corps des Mines, he notably contributed to the development of the Culture Pass and led the digital service of the Ministry of Culture.
At Qubit Pharmaceuticals, his remit will be to lead the industrialization of the company’s technological backbone, built on the integration of high-performance computing, quantum chemistry algorithms and artificial intelligence, and a cloud-native molecular-simulation platform.
“My mission is at the heart of this transformation, which makes the product the engine of research, not just its end result,” says Romain Delassus.
In May 2025, Qubit Pharmaceuticals announced that it had deployed the world’s most powerful AI foundation model for molecular simulation in the field of pharmaceutical chemistry. This model, named FeNNix-Bio1, marks a major technological milestone in the company’s strategy.
Founded in France, Qubit Pharmaceuticals positions itself at the crossroads of pharmacy, quantum physics, and computational sciences, with the aim of accelerating and making drug discovery more reliable through simulation.
